Shire Proposes Combination With Baxalta to Create the Leading Global Biotech Company Focused on Rare Diseases PR Newswire DUBLIN, August 4, 2015 DUBLIN , August 4, 2015 /PRNewswire/ — Strong strategic fit and industry-leading portfolio of combined company is projected to deliver immediate value creation and generate $20 billion in product sales by 2020 Complementary capabilities create leading platform for growth, with over 30 planned product launches and the industry ‘ s largest rare diseases portfolio with 50-plus projects Transaction expected to generate double-digit top-line growth; strong returns and attractive value creation; breakeven to Non GAAP EPS in year one with accretion thereafter Combination offers significant operating synergy potential and a compelling tax profile (projected 16%-17% combined Non GAAP effective tax rate by 2017) , generating an IRR in excess of 10% All-stock transaction of approximately $30 billion represents im mediate value creation for Baxalta shareholders th rough a substantial premium of 3 6 % and allows for participation in future upside Shire urges Baxalta to engage in a negotiated transaction Shire plc (LSE: SHP, NASDAQ: SHPG) today confirms that it made a proposal to Baxalta Incorporated (NYSE: BXLT) on July 10, 2015 , to combine the companies in an all-stock transaction pursuant to which Baxalta shareholders would receive, for each Baxalta share, 0.1687 Shire ADRs. The proposal implies a value of $45.23 per Baxalta share and represents a significant premium of 36% over Baxalta’s stock price as of August 3, 2015 . […]
